Financial Impact Preview

TEM plans to provide further detail on the transaction’s financial impact during its second‑quarter earnings call on July 30, as it works toward a positive adjusted EBITDA and free‑cash‑flow outlook in 2027 while leveraging the expanding demand for precision oncology and MRD testing.